Larimar Therapeutics
LRMR
81 hedge funds and large institutions have $43.4M invested in Larimar Therapeutics in 2016 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 23 reducing their positions, and 11 closing their positions.
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
5% more funds holding
Funds holding: 77 → 81 (+4)
4.16% more ownership
Funds ownership: 0% → 4.16% (+4.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 23
5% less capital invested
Capital invested by funds: $45.9M → $43.4M (-$2.46M)
72% less call options, than puts
Call options by funds: $140K | Put options by funds: $495K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$2.03M |
| 2 |
AG
Artal Group
Luxembourg
|
+$1.69M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.05M |
| 4 |
Millennium Management
New York
|
+$896K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$374K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
VHCP Management
New York
|
-$1.99M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.59M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$933K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$810K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$498K |
LRMR Hedge Fund Activity: Q4 2016 in Review
81 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q4 2016, worth a combined $43.4M — down 5.4% from $45.9M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LRMR positions and 11 closed out — a net gain of 5 holders — while 23 added to existing stakes and 23 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $2.03M. The largest seller was VHCP Management, exiting entirely with an estimated $1.99M sold.
- 81 institutional investors held Larimar Therapeutics (LRMR) as of Q4 2016, up from 77 in Q3 2016.
- Funds reported $43.4M of Larimar Therapeutics stock for Q4 2016, down 5.4% quarter-over-quarter.
- 16 funds opened new Larimar Therapeutics positions in Q4 2016 and 11 closed out, a net change of +5 holders.
- The largest Larimar Therapeutics buyer in Q4 2016 was 683 Capital Management, an estimated $2.03M added.
- The largest Larimar Therapeutics seller in Q4 2016 was VHCP Management, an estimated $1.99M sold.
Based on aggregated 13F filings for Q4 2016.